Role of rituximab in the treatment of systemic sclerosis: A literature review

Hajime Yoshifuji, Keina Yomono, Yasuhiko Yamano, Yasuhiro Kondoh, Hidekata Yasuoka

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

This literature review aimed to evaluate the effectiveness of rituximab (RTX) in patients with systemic sclerosis (SSc). PubMed was searched for articles, published through 31 March 2022, on any controlled studies using RTX in the treatment of SSc. Of 85 identified articles, 9 were selected by title/abstract screening and full text examination. All nine articles reported outcomes of forced vital capacity (%FVC), and seven reported those of modified Rodnan skin scores (mRSS). The results showed that among the seven controlled studies evaluating skin lesions in patients with SSc, four showed a significant improvement of mRSS by RTX when compared with a control group, whereas three showed no significant effect. Among the nine controlled studies evaluating lung lesions, five showed a significant improvement of %FVC compared with a control group, whereas four showed no significant effect. In conclusion, RTX may be effective in the treatment of skin and lung lesions in patients with SSc. The profiles of SSc patients for whom RTX was indicated were unclear, although patients with diffuse cutaneous SSc and those positive for anti-topoisomerase I antibody were considered potential targets. Additional studies are needed to assess the long-term effectiveness of RTX in the treatment of patients with SSc.

Original languageEnglish
Pages (from-to)1068-1077
Number of pages10
JournalModern Rheumatology
Volume33
Issue number6
DOIs
Publication statusPublished - 01-11-2023

All Science Journal Classification (ASJC) codes

  • General Medicine

Fingerprint

Dive into the research topics of 'Role of rituximab in the treatment of systemic sclerosis: A literature review'. Together they form a unique fingerprint.

Cite this